Suman K. Ray, Yamini Meshram and Sukhes Mukherjee* Pages 221 - 236 ( 16 )
Cancer immunotherapy endeavours in harnessing the delicate strength and specificity of the immune system for therapy of different malignancies, including colorectal carcinoma. The recent challenge for cancer immunotherapy is to practice and develop molecular immunology tools to create tactics that efficiently and securely boost antitumor reactions. After several attempts of deceptive outcomes, the wave has lastly altered and immunotherapy has become a clinically confirmed treatment for several cancers. Immunotherapeutic methods include the administration of antibodies or modified proteins that either block cellular activity or co-stimulate cells through immune control pathways, cancer vaccines, oncolytic bacteria, ex vivo activated adoptive transfer of T cells and natural killer cells. Engineered T cells are used to produce a chimeric antigen receptor (CAR) to treat different malignancies, including colorectal carcinoma in a recent decade. Despite the considerable early clinical success, CAR-T therapies are associated with some side effects and sometimes display minimal efficacy. It gives special emphasis on the latest clinical evidence with CAR-T technology and also other related immunotherapeutic methods with promising performance, and highlighted how this therapy can affect the therapeutic outcome and next upsurge as a key clinical aspect of colorectal carcinoma. In this review, we recapitulate the current developments produced to improve the efficacy and specificity of CAR-T therapies in colon cancer.
Cancerimmunotherapy, colorectal carcinoma, CAR-T technology, combination therapies, neoplastic cells, transformation, tumor cells.
Independent Researcher, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh-462020, Independent Researcher, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh-462020, Department of Biochemistry, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh-462020